Leucemia linfoblástica aguda infantil. Seguimiento post-finalización del tratamieto en 430 pacientes

Vergara Domínguez, Berta; Svarch Guerchicoff, Eva; González Otero, Alejandro; Machín García, Sergio; Campos Díaz, Mirta; González Seivanes, Fernando; Martínez Cárdenas, Liliana; Cedré Hernández, Tamara; Pichs León, Victor; López García, Carmen; Castro Martínez, María E.
Rev Esp Pediatr ; v. 60(5)2004. tab
Artículo en Español | CUMED | ID: cum-31686

Documentos relacionados

  1. Myosin 1g as a high-risk biomarker in a pediatric patient with lineage switch from acute lymphoblastic leukemia to myeloid phenotype.
  2. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel.
  3. Modulation of CD19 surface expression in B cell acute lymphoblastic leukemia.
  4. [Updated AWMF Guideline on the Diagnosis and Treatment of Acute Lymphoblastic Leukaemia in Children].
  5. The emerging use of chemotherapy-free regimens in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
  6. How should childhood acute lymphoblastic leukemia relapses in low-income and middle-income countries be managed: The AHOPCA-ALL study group experience.
  7. Current Management and New Developments in the Treatment of ALL.
  8. [Neurocognitive function of acute lymphoblastic leukemia survivors treated only with chemotherapy].
  9. Effect of chemotherapy (with and without radiotherapy) on the intelligence of children and adolescents treated for acute lymphoblastic leukemia; a meta-analysis.
  10. Late isolated central nervous system relapse in childhood B-cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: A report from the Children's Oncology Group study AALL02P2.